A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Author:
Funder
JSPS KAKENHI
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference50 articles.
1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017
3. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials;Lytvyn;Circulation,2017
4. Sympathetic drive in anterior and inferior uncomplicated acute myocardial infarction;Graham;Circulation,2004
5. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure;Leimbach;Circulation,1986
Cited by 126 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus;Scientific Reports;2023-12-03
2. The Sympathetic Nervous System in Hypertensive Heart Failure with Preserved LVEF;Journal of Clinical Medicine;2023-10-12
3. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease;Frontiers in Immunology;2023-09-21
4. Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction;The Journal of Physiological Sciences;2023-09-13
5. The Impact of Pharmacotherapy for Heart Failure on Oxidative Stress—Role of New Drugs, Flozins;Biomedicines;2023-08-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3